GHRP and Mod GRF 1-29 lost hype to newer compounds

Newer peptides offer stronger, more consistent growth signals

Multiple daily dosing made protocols inconvenient for users

Short half-life reduced practicality compared to longer-acting options

MK-677 popularity replaced frequent injection peptide stacks

CJC-1295 with DAC simplified dosing schedules significantly

Appetite spikes from GHRP discouraged many users long-term

Results felt subtle compared to modern peptide expectations

More potent fat loss agents shifted focus away

Market trends favor convenience over complicated dosing protocols

Injection fatigue reduced adherence among casual bodybuilding users

Cost versus benefit less appealing than newer options

Better understanding of GH pulsatility changed protocol preferences

Quality control issues hurt trust in early peptide suppliers

Stacks required precision timing, difficult for average users